BioCentury | Oct 17, 2016
Clinical News

Kazano regulatory update

...EU for the indication. Furiex Pharmaceuticals Inc. co-developed alogliptin, a dipeptidyl peptidase-4 (DDP-4) inhibitor, with Syrrx Inc....
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...in new geographies. The buying spree started with the 2005 acquisition of structural biology company Syrrx Inc....
...cash, followed by the acquisition of Paradigm Therapeutics Ltd. for an undisclosed amount in 2007. Syrrx...
...U.S. and five in Europe and Japan. Takeda gained trelagliptin through its 2005 acquisition of Syrrx Inc....
BioCentury | Jun 2, 2014
Clinical News

Nesina alogliptin regulatory update

...inhibitors, thiazolidinediones, sulfonylurea or biguanide. Furiex co-developed alogliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Mar 10, 2014
Clinical News

Trelagliptin regulatory update

...gained rights to the once-weekly oral dipeptidyl peptidase-4 (DPP-4) inhibitor through its 2005 acquisition of Syrrx Inc....
BioCentury | Sep 30, 2013
Clinical News

Incresync alogliptin/pioglitazone regulatory update

...milestones, plus EU royalties of 4-8%. Furiex co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Sep 30, 2013
Clinical News

Vipdomet alogliptin/metformin regulatory update

...milestones, plus EU royalties of 4-8%. Furiex co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Sep 30, 2013
Clinical News

Vipidia alogliptin regulatory update

...milestones, plus EU royalties of 4-8%. Furiex co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Sep 30, 2013
Finance

Regulatory milestones

...payment to Furiex, which co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc. Takeda acquired Syrrx...
BioCentury | Sep 25, 2013
Company News

EC approves three Takeda diabetes products

...products Vipdomet alogliptin/metformin and Incresync alogliptin/pioglitazone. Furiex co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Sep 9, 2013
Clinical News

Nesina alogliptin: Phase III data

...in Japan, and all 3 products are under review in Europe. Furiex co-developed alogliptin with Syrrx Inc....
Items per page:
1 - 10 of 149
BioCentury | Oct 17, 2016
Clinical News

Kazano regulatory update

...EU for the indication. Furiex Pharmaceuticals Inc. co-developed alogliptin, a dipeptidyl peptidase-4 (DDP-4) inhibitor, with Syrrx Inc....
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...in new geographies. The buying spree started with the 2005 acquisition of structural biology company Syrrx Inc....
...cash, followed by the acquisition of Paradigm Therapeutics Ltd. for an undisclosed amount in 2007. Syrrx...
...U.S. and five in Europe and Japan. Takeda gained trelagliptin through its 2005 acquisition of Syrrx Inc....
BioCentury | Jun 2, 2014
Clinical News

Nesina alogliptin regulatory update

...inhibitors, thiazolidinediones, sulfonylurea or biguanide. Furiex co-developed alogliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Mar 10, 2014
Clinical News

Trelagliptin regulatory update

...gained rights to the once-weekly oral dipeptidyl peptidase-4 (DPP-4) inhibitor through its 2005 acquisition of Syrrx Inc....
BioCentury | Sep 30, 2013
Clinical News

Incresync alogliptin/pioglitazone regulatory update

...milestones, plus EU royalties of 4-8%. Furiex co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Sep 30, 2013
Clinical News

Vipdomet alogliptin/metformin regulatory update

...milestones, plus EU royalties of 4-8%. Furiex co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Sep 30, 2013
Clinical News

Vipidia alogliptin regulatory update

...milestones, plus EU royalties of 4-8%. Furiex co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Sep 30, 2013
Finance

Regulatory milestones

...payment to Furiex, which co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc. Takeda acquired Syrrx...
BioCentury | Sep 25, 2013
Company News

EC approves three Takeda diabetes products

...products Vipdomet alogliptin/metformin and Incresync alogliptin/pioglitazone. Furiex co-developed alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc....
BioCentury | Sep 9, 2013
Clinical News

Nesina alogliptin: Phase III data

...in Japan, and all 3 products are under review in Europe. Furiex co-developed alogliptin with Syrrx Inc....
Items per page:
1 - 10 of 149